PREVNAR 13
Biological
PFIZER INC.
Total Payments
$13.0M
Transactions
67,748
Doctors
33,559
Companies
7
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $976,782 | 149 | 122 |
| 2023 | $1.6M | 9,911 | 7,603 |
| 2022 | $894,843 | 15,587 | 11,316 |
| 2021 | $3.2M | 27,605 | 17,395 |
| 2020 | $5.1M | 14,024 | 9,379 |
| 2019 | $1.3M | 237 | 205 |
| 2018 | $10,665 | 143 | 138 |
| 2017 | $7,182 | 92 | 87 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $11.5M | 1,099 | 88.8% |
| Food and Beverage | $1.2M | 66,496 | 9.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $149,767 | 102 | 1.2% |
| Consulting Fee | $74,200 | 10 | 0.6% |
| Honoraria | $28,900 | 11 | 0.2% |
| Travel and Lodging | $15,584 | 21 | 0.1% |
| Space rental or facility fees (teaching hospital only) | $11,500 | 9 | 0.1% |
Payments by Type
Research
$11.5M
1,099 transactions
General
$1.5M
66,649 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| CRCCONTINUATION OF ASSESSMENT OF THE IMPACT OF PREVNAR 13 13VPNC ON INVASIVE PNEUMOCOCCAL DISEASE CAUSED BY VACCINE SEROTYPES OF STREPTOCOCCUS PNEUMONIAE AFTER INTRODUCTION INTO ROUTINE PEDIATRIC USE FOR THE PERIOD OF MAY 2015 APRIL 2020 | PFIZER INC. | $1.5M | 0 |
| DETERMINATION OF THE UTILITY OF PFIZERS PNEUMOCOCCAL URINE ANTIGEN TEST IN CHILDRENS 5 YEARS OF AGE OR YOUNGER WITH COMMUNITY ACQUIRED PNEUMONIA IN THE UNITED STATES | PFIZER INC. | $1.3M | 0 |
| SEROTYPE DISTRIBUTION OF STREPTOCOCCUS PNEUMONIA IN COMMUNITYACQUIRED PNEUMONIA IN HOSPITALIZED ADULTS 18 YEARS OF AGE IN THE UNITED STATES | PFIZER INC. | $1.2M | 0 |
| A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER | PFIZER INC. | $818,514 | 0 |
| A PHASE 2 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE GIVEN WITH OR SEPARATELY FROM 13VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | PFIZER INC. | $778,240 | 0 |
| THE UNITED STATES PEDIATRIC MULTICENTER PNEUMOCOCCAL SURVEILLANCE | PFIZER INC. | $759,760 | 1 |
| A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS | PFIZER INC. | $566,585 | 0 |
| ANTIPNEUMOCOCCAL EFFECTS OF THE RABIES VACCINE | PFIZER INC. | $449,282 | 0 |
| DETERMINATION OF THE UTILITY OF PFIZERS PNEUMOCOCCAL URINE ANTIGEN TEST IN CHILDREN UNDER 6 YEARS OF AGE WITH COMMUNITY ACQUIRED PNEUMONIA IN THE UNITED STATESWI258441 | PFIZER INC. | $419,299 | 0 |
| PNEUMOCOCCAL VACCINATION STATUS AND INCIDENT CARDIOVASCULAR DISEASE IN US NURSING HOMES EPIDEMIOLOGIC STUDY | PFIZER INC. | $399,648 | 0 |
| A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE | PFIZER INC. | $323,039 | 0 |
| CRCPREDICTORS OF PNEUMOCOCCAL VACCINATION PNEUMOCOCCAL VACCINE EFFECTIVENESS AND TRENDS IN PNEUMONIA | PFIZER INC. | $314,744 | 0 |
| DETERMINATION OF THE UTILITY OF PFIZERS PNEUMOCOCCAL URINE ANTIGEN TEST IN CHILDREN 5 YEARS OF AGE OR YOUNGER WITH COMMUNITY ACQUIRED PNEUMONIA IN THE UNITED STATESWI253501 | PFIZER INC. | $292,403 | 0 |
| A PHASE 2 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINES IN HEALTHY INFANTS | PFIZER INC. | $242,222 | 0 |
| ETIOLOGY OF EMPYEMA IN CHILDREN YOUNGER THAN 18 YEARS OLD IN ORANGE COUNTY CALIFORNIA A ROLE FOR MOLECULAR DIAGNOSIS | PFIZER INC. | $225,169 | 0 |
| DETERMINATION OF THE UTILITY OF PFIZERS PNEUMOCOCCAL URINE ANTIGEN TEST IN CHILDRENS 5 YEARS OF AGE OR YOUNGER WITH COMMUNITY ACQUIRED PNEUMONIA IN THE UNITED STATESWI253501 | PFIZER INC. | $220,750 | 0 |
| A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION | PFIZER INC. | $217,727 | 0 |
| CONJUGATE VS CARBOHYDRATE VACCINE COMPARATIVE STUDYWI233503 | PFIZER INC. | $192,454 | 0 |
| CONJUGATE VS CARBOHYDRATE VACCINE COMPARATIVE STUDY | PFIZER INC. | $167,099 | 0 |
| CLINICAL VALIDATION AND DETERMINATION OF APPROPRIATE CUTOFFS FOR PNEUMOCOCCAL URINE ANTIGEN TEST IN CHILDREN UNDER 5 YEARS OF AGE WITH COMMUNITY ACQUIRED PNEUMONIA IN GUATEMALA | PFIZER INC. | $143,184 | 0 |
Top Doctors Receiving Payments for PREVNAR 13 — Page 1343
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , PA-C | Physician Assistant | Colorado Springs, CO | $1.55 | 1 |
| , MD | Family Medicine | Colorado Springs, CO | $1.55 | 1 |
| , FNP | Family | Knoxville, TN | $1.45 | 1 |
| , MD | Internal Medicine | Knoxville, TN | $1.45 | 1 |
| , MD | Pediatrics | Gulf Breeze, FL | $1.31 | 1 |
| , MD | Family Medicine | Oak Creek, WI | $1.20 | 1 |
| , M.D | Internal Medicine | Houston, TX | $1.19 | 1 |
| , NP | Family | Westland, MI | $0.86 | 1 |
| , MD | Family Medicine | Hattiesburg, MS | $0.84 | 1 |
| , NP | Nurse Practitioner | Camillus, NY | $0.76 | 1 |
Ad
Manufacturing Companies
- PFIZER INC. $12.9M
- PFIZER INTERNATIONAL LLC $56,395
- PFIZER PHARMACEUTICALS LLC $11,294
- PBG PUERTO RICO LLC $9,095
- PFIZER S.A. $4,403
- Pfizer Inc. $3,515
- ARRAY BIOPHARMA INC $39.62
Product Information
- Type Biological
- Total Payments $13.0M
- Total Doctors 33,559
- Transactions 67,748
About PREVNAR 13
PREVNAR 13 is a biological associated with $13.0M in payments to 33,559 healthcare providers, recorded across 67,748 transactions in the CMS Open Payments database. The primary manufacturer is PFIZER INC..
Payment data is available from 2017 to 2024. In 2024, $976,782 was paid across 149 transactions to 122 doctors.
The most common payment nature for PREVNAR 13 is "Unspecified" ($11.5M, 88.8% of total).
PREVNAR 13 is associated with 20 research studies, including "CRCCONTINUATION OF ASSESSMENT OF THE IMPACT OF PREVNAR 13 13VPNC ON INVASIVE PNEUMOCOCCAL DISEASE CAUSED BY VACCINE SEROTYPES OF STREPTOCOCCUS PNEUMONIAE AFTER INTRODUCTION INTO ROUTINE PEDIATRIC USE FOR THE PERIOD OF MAY 2015 APRIL 2020" ($1.5M).